15 Jan Mytos
Ali Afshar, Ph.D., CEO and Co-Founder
April 29 | 9:00am | Salone dei Cavalieri, Section 1
London, UK
(Private)
Mytos runs fully-automated stem cell manufacturing sites powered by our iDEM automation platform – to scale stem cell-derived therapies to millions of patients rapidly at lower cost. Manual manufacturing at CDMOs has held back Regenerative Medicine due to high costs and high failure rates. With Mytos ’ automated CDMO, these therapies can now be scaled globally at low cost. We’ve announced partnerships across multiple therapies so far ranging from Parkinson’s, to hearing loss, to bone repair. Within the next 12- 18 months , cells grown on our machines will be going into patients – and our first site will be licensed for releasing patient batches by September.
